What are the drug interactions of ropinirole (Requip)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 12, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Requip (Ropinirole) Drug Interactions

Ropinirole has three clinically significant drug interactions that require dose adjustment or monitoring: CYP1A2 inhibitors/inducers, hormone replacement therapy, and dopamine antagonists 1.

Major Drug Interactions

CYP1A2 Inhibitors and Inducers

The most clinically important interactions involve medications that affect the CYP1A2 enzyme system, which is the primary metabolic pathway for ropinirole 1:

CYP1A2 Inhibitors (increase ropinirole levels):

  • Ciprofloxacin: Increases ropinirole AUC by 84% and Cmax by 60% - dose reduction of ropinirole is required 1
  • Fluvoxamine: Expected to significantly increase ropinirole levels
  • Mexiletine: Expected to increase ropinirole levels
  • Older fluoroquinolones (norfloxacin): Expected to increase ropinirole levels

CYP1A2 Inducers (decrease ropinirole levels):

  • Cigarette smoking: Reduces ropinirole Cmax by ~30% and AUC by 38% - dose increase may be needed 1. A case report documented profound side effects when a patient on stable ropinirole stopped smoking 2
  • Omeprazole: Expected to reduce ropinirole levels

Hormone Replacement Therapy (HRT)

  • Estrogens (particularly ethinylestradiol) reduce ropinirole oral clearance by 36% 1
  • Starting or stopping HRT requires ropinirole dose adjustment - expect to need lower doses when starting HRT and higher doses when stopping

Dopamine Antagonists

  • Neuroleptics and metoclopramide may reduce the efficacy of ropinirole by blocking dopamine receptors 1
  • Avoid concurrent use when possible, as these agents work in opposition

Drugs WITHOUT Significant Interactions

The following medications have been studied and show no clinically significant interactions with ropinirole:

  • Theophylline: No interaction despite both being CYP1A2 substrates 1, 3
  • Digoxin: No effect on steady-state pharmacokinetics 1
  • Levodopa/carbidopa: No effect on ropinirole pharmacokinetics; ropinirole increases L-dopa Cmax by 20% but AUC unchanged 1
  • Common PD medications: Selegiline, amantadine, anticholinergics show no interaction 1
  • Other common drugs: Benzodiazepines, tricyclic antidepressants, ibuprofen, thiazides, antihistamines 1

Clinical Pitfalls and Monitoring

Key considerations:

  • When initiating CYP1A2 inhibitors (especially ciprofloxacin), reduce ropinirole dose and monitor for increased side effects (somnolence, dizziness, hallucinations)
  • Counsel patients about smoking cessation - they may experience toxicity if ropinirole dose is not reduced when quitting
  • Women starting or stopping HRT need dose adjustments
  • Ropinirole does not inhibit or induce P450 enzymes, so it won't affect other drugs' metabolism 1
  • The drug is not a P-glycoprotein substrate, limiting additional interaction potential 1

Important context: While these interactions exist, the 2025 AASM guidelines suggest against standard use of ropinirole for RLS due to augmentation risk with long-term use, though it may be considered for short-term symptom reduction 4.

References

Research

Adverse effects of ropinirole-treated restless leg syndrome (RLS) during smoking cessation.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2008

Guideline

treatment of restless legs syndrome and periodic limb movement disorder: an american academy of sleep medicine clinical practice guideline.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.